Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 39 from EUR 41 and keeps an Underweight rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Reports Strong Q3 2025 Growth
- Fresenius Medical Care Reports Strong Q3 Earnings
- Fresenius Medical reports Q3 adjusted EPS EUR1.10 vs. EUR0.81 last year
- Fresenius Medical still sees 2025 revenue growth in low-single digits
- Fresenius Medical Care Reports Strong Q3 2025 Results and Strategic Progress